Interaction Checker

Interacciones de Dasatinib

Dasatinib (Sprycel, Phyrago) tiene 152 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 69; moderadas: 30; leves: 53; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (69)

  • AmiodaronaantiarrítmicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Antiácidos (Tums, Maalox, Mylanta)Productos sin recetaGrave

    Antacids: Avoid concomitant use. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • AtazanavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Bicarbonato de sodioantiácidoGrave

    Antacids: Avoid concomitant use. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Bosentáninductor de CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • CiclosporinainmunosupresorGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • ClobazambenzodiazepinaGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • DarunavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • DexametasonacorticosteroideGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • DronedaronaantiarrítmicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • EfavirenzantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • EslicarbazepinaanticonvulsivoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • EtravirinaantirretroviralGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • EverolimusinmunosupresorGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • FosamprenavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Ibuprofeno y famotidinaAINEGrave

    Intervention Concomitant administration of ibuprofen and famotidine tablet is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. (etiqueta de Ibuprofeno y famotidina, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • IsoniazidaantibióticoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Ketoconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • LenacapavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • NefazodonaantidepresivoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • NevirapinaantirretroviralGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Omeprazol y bicarbonato de sodioinhibidor de la bomba de protonesGrave

    Antacids: Avoid concomitant use. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • PerampanelanticonvulsivoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Posaconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • PrimidonaanticonvulsivoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • RifabutinaantibióticoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • RifampicinaantibióticoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • RifapentinaantibióticoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • RitonavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Suvorexantsedante-hipnóticoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Ticagrelorantiagregante plaquetarioGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (etiqueta de Dasatinib, Interacciones medicamentosas)

Interacciones moderadas (30)

  • AdenosinaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • ApixabánanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

  • ArgatrobánanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

  • BivalirudinaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

  • DabigatránanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Dexlansoprazolinhibidor de la bomba de protonesModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (etiqueta de Dexlansoprazol, Interacciones medicamentosas)

  • Digoxinaglucósido digitálicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • DisopiramidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • DofetilidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • EdoxabánanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

  • EnoxaparinaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

  • EsmololbetabloqueanteModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • Esomeprazolinhibidor de la bomba de protonesModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole… (etiqueta de Esomeprazol, Interacciones medicamentosas)

  • FlecainidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • FondaparinuxanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

  • HeparinaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

  • IbutilidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • Lansoprazolinhibidor de la bomba de protonesModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (etiqueta de Lansoprazol, Interacciones medicamentosas)

  • Lidocaínaanestésico localModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • Lidocaína y prilocaínaanestésico localModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • MexiletinaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • Omeprazolinhibidor de la bomba de protonesModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (etiqueta de Omeprazol, Interacciones medicamentosas)

  • Pantoprazolinhibidor de la bomba de protonesModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (etiqueta de Pantoprazol, Interacciones medicamentosas)

  • ProcainamidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • PropafenonaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • QuinidinaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • Rabeprazolinhibidor de la bomba de protonesModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (etiqueta de Rabeprazol, Interacciones medicamentosas)

  • RivaroxabánanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

  • SotalolbetabloqueanteModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • WarfarinaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (etiqueta de Dasatinib, Advertencias y precauciones)

Menciones leves (53)

  • Acetazolamidainhibidor de la anhidrasa carbónicaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Ácido etacrínicodiurético de asaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Amiloridadiurético ahorrador de potasioLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Atenolol y clortalidonabetabloqueanteLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Azelastina y fluticasonaantihistamínicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • BeclometasonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Benazepril e hidroclorotiazidainhibidor de la ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • BetametasonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Bisoprolol e hidroclorotiazidabetabloqueanteLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • BudesonidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Bumetanidadiurético de asaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • CiclesonidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • ClobetasolcorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Clorotiazidadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Clortalidonadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • DeflazacortcorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • DesonidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Enalapril e hidroclorotiazidainhibidor de la ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Eplerenonaantagonista de la aldosteronaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Espironolactonaantagonista de la aldosteronaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • FludrocortisonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • FlunisolidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • FluocinonidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • FluticasonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Fosinopril e hidroclorotiazidainhibidor de la ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Furosemidadiurético de asaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • HalobetasolcorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Hidroclorotiazidadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • HidrocortisonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Indapamidadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Lisinopril e hidroclorotiazidainhibidor de la ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • MetilprednisolonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Metolazonadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Metoprolol e hidroclorotiazidabetabloqueanteLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • MometasonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • PrednisolonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • PrednisonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Quinapril e hidroclorotiazidainhibidor de la ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Torasemidadiurético de asaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • TriamcinolonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Triamterenodiurético ahorrador de potasioLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

Compruebe Dasatinib frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.